Caffeine (1,3,7-trimethylxantine) is the most commonly consumed social drug in western society for increased physical and cognitive performance [1][2][3][4][5], and it is the main ergogenic resource used by athletes [6]. Initially controversial, caffeine was banned by the International Olympic Committee from 1980-2003 [1,6,7], but then in 2004 its use was approved by the World Anti-doping Agency (WADA), and later this year by the U.S. Anti-doping Agency (USADA; 2016). However, caffeine has remained on the lists of monitored substances of these anti-doping agencies. Caffeine is rapidly and completely absorbed by the gastrointestinal tract and is readily distributed throughout all tissues of the body, including muscles and the central nervous system (CNS), which are believed to be the main recipients of caffeine's ergogenic effects [2,14]. Ergogenic doses of caffeine ranging from 3 to 9 mg/kg body mass [6] appear to have no adverse effects. A moderate oral dose of 6 mg/ kg body mass, which elicits peak plasma levels of about 60 µmol/L concentrations after 30 to 60 min, with half-life for elimination range between 2.5-10 h, is known to enhance physical and cognitive performance [5,6,10,14,15]. Blood levels of 1 -2 mmol/L are known to be toxic and even lethal [14], and have been associated with suicides [16]. Caffeine's molecular mechanisms for increasing physical performance are still virtually undefined. However, due to its ability to cross the blood-brain barrier at blood concentrations generated by a moderate ergogenic dose, and because of its properties as a stimulant psychotropic drug [15,17], mechanisms involving metabolic and central effects have been proposed.Metabolic effects of caffeine have been mainly related to the enhancement of lipolysis, fatty acid oxidation and energy expenditure via the stimulation of the sympathetic nervous system [18,19] and a sequential sparing of muscle glycogen [20]. However, the main pharmacological effects of caffeine appear to be mediated via the CNS where caffeine counterbalances the inhibitory neuromodulation of adenosine in order to induce effects on both the CNS and peripheral nervous system to reduce pain and exertion perception [21], to improve motor recruitment [22] and to increase excitation-contraction coupling [23,24].Caffeine is a non-selective competitive adenosine receptor antagonist (A 1 R and A 2 AR subtypes) that increases neurotransmission via dopamine D 2 receptors (D 2 R) [25,26]. The striatum expresses high levels of A 2 AR where they are co-expressed with postsynaptic D 2 R, forming A 2 AR-D 2 R heterodimers [25]. In this scenario, caffeine fails to be ergogenic in the mouse lacking A 2 AR [27], or in wild type rats treated with the selective A 2 AR agonist 5'-N-ethylcarboxamidoadenosine (NECA) [26], which denotes the participation of these receptors in caffeine's central-mediated ergogenic effects.When designing experimental models to better define the molecular mechanisms involved in the enhanced capacity of caffeine to positively modulate physical ...